Statin use is associated with a lower risk of diffuse large B-cell lymphoma: A systematic review and meta-analysis.

Abstract

e13585 Background: Statin use is associated with decreased risk of several types of cancer such as hepatocellular carcinoma, colorectal cancer and hematologic malignancy, although the data on diffuse large B-cell lymphoma (DLBCL) is still inconclusive. The current systematic review and meta-analysis was conducted to summarize all available data on this association. Methods: A systematic review was performed using EMBASE and MEDLINE database from inception to October 2019 with search strategy that included terms for “statin” and “DLBCL”. Eligible studies could be either cohort or case-control studies that reported the association between statin use and risk of DLBCL. Eligible cohort studies must include patients with history of statin use and comparators with no history of statin use, then follow them for incident DLBCL and report the relative risk, hazard risk ratio, or standardized incidence ratio and associated 95% confidence intervals (CI) comparing the incidence of DLBCL between the two groups. Eligible case-control studies must include cases with DLBCL and controls without DLBCL, then search for prior statin use and report the odds ratio and associated 95% CI for this association. Point estimates along with standard errors were extracted and combined together for the calculation of the pooled effect estimate using the random effect, generic inverse variance method. Results: A total of 1,139 articles were identified using the search strategy. Six studies satisfied the inclusion criteria and were included into the meta-analysis. Statin use was associated with a significantly reduced risk of DLBCL with the pooled relative risk of 0.70 (95% CI, 0.56 – 0.88; I2 = 70%). Funnel plot was fairly symmetric and was not suggestive of presence of publication bias. Conclusions: This systematic review and meta-analysis found that patients with history of statin use had a significantly lower risk of DLBCL compared to individuals without history of statin use.